{"id":"tadalafil-versus-tamsulosin-as-met","safety":{"commonSideEffects":[{"rate":"10-15","effect":"Headache"},{"rate":"5-10","effect":"Dyspepsia"},{"rate":"5-10","effect":"Back pain"},{"rate":"5-10","effect":"Dizziness"},{"rate":"5-10","effect":"Orthostatic hypotension"},{"rate":"5-15","effect":"Retrograde ejaculation"}]},"_chembl":{"chemblId":"CHEMBL1200914","moleculeType":"Small molecule","molecularWeight":"444.98"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This appears to be a comparative study (versus) rather than a single drug entity. Tadalafil works by inhibiting PDE5, increasing cGMP levels and promoting smooth muscle relaxation in lower urinary tract tissues. Tamsulosin selectively antagonizes alpha-1A receptors on prostatic smooth muscle, reducing dynamic obstruction. Both are used for benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS) but through distinct mechanisms.","oneSentence":"Tadalafil is a phosphodiesterase-5 inhibitor that relaxes smooth muscle in the prostate and bladder, improving urinary flow; tamsulosin is an alpha-1A adrenergic antagonist that selectively blocks receptors in the prostate to reduce urinary obstruction.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:10:57.885Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Benign prostatic hyperplasia with lower urinary tract symptoms"},{"name":"Erectile dysfunction (tadalafil)"}]},"trialDetails":[{"nctId":"NCT04641507","phase":"PHASE4","title":"Comparative Study Between Tadalafil Versus Tamsulosin as a Medical Expulsive Therapy for Lower Ureteric Stones","status":"UNKNOWN","sponsor":"Beni-Suef University","startDate":"2020-01-01","conditions":"Lower Ureteric Stones","enrollment":166}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Tadalafil versus tamsulosin as MET","genericName":"Tadalafil versus tamsulosin as MET","companyName":"Beni-Suef University","companyId":"beni-suef-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tadalafil is a phosphodiesterase-5 inhibitor that relaxes smooth muscle in the prostate and bladder, improving urinary flow; tamsulosin is an alpha-1A adrenergic antagonist that selectively blocks receptors in the prostate to reduce urinary obstruction. Used for Benign prostatic hyperplasia with lower urinary tract symptoms, Erectile dysfunction (tadalafil).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}